Femasys stock.

According to 3 stock analysts, the average 12-month stock price forecast for Femasys stock is $9.00, which predicts an increase of 845.18%. The lowest target is $7.00 and the highest is $10. On average, analysts rate Femasys stock as a strong buy.According to Accountingbase.com, common stock is neither an asset nor a liability; it is considered equity. Equity is basically considered to mathematically be the difference between the total assets and total liabilities of a company.Femasys Inc.is a biomedical company focused on transforming women's healthcare by developing novel solutions as well as providing significant clinical impact to address severely underserved areas. The company's lead product candidates offer FemBloc and FemaSeed. Femasys Inc. is based in ATLANTA. Stock split history for Femasys since 2021.Femasys : Corporate Presentation June 2023. Disrupting Convention in Women's Health Through Continuous Innovation. This Presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business, operations and financial conditions, including but not …

Femasys (FEMY) stock price is up 1,250% but there are 2 key risks. The remarkable Femasys (NASDAQ: FEMY) stock price comeback continued on Monday as demand for the shares continued. The shares surged by more than 45% on Friday and gained by another 15% in the pre-mar... 7 weeks ago - Invezz.ATLANTA, July 27, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting women’s unmet needs worldwide by developing a suite of product candidates and products that include minimally invasive, in-office technologies for reproductive health, announced that the United States Patent and …

Femasys-stock Femasys Inc Registered Shs Stock , FEMY 0.95 -0.01 -1.53% After-market 07:34:36 PM EDT 11/17/2023 NAS Add to watchlist 0.96 +0.04 …Web

Femasys (NASDAQ:FEMY) filed a prospectus related to the offer and resale by the selling stockholders of up to an aggregate of 18.11M shares of common stock This prospectus is not an offer to sell.PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (PharmaCyte or the Company) announces it has made a $5 million investment in Femasys, Inc. (Nasdaq:FEMY) (Femasys), a biomedical company focused on meeting... Femasys Inc. Announces Financial Results for the Third Quarter Ended September 30, 2023 and Provides Corporate Update Globe Newswire • …You may have a lot of questions if you are interested in investing in the stock market for the first time. One question that beginning investors often ask is whether they need a broker to begin trading.Nov 28, 2023 · Femasys, a medical device company, is set to launch its minimally invasive reproductive health products for women in 2024. ... Its stock ran from $0.33 to an intraday high of $4.75 a few days ... Femasys : FEMY got FDA ... This revolutionary clearance has primed ICU for an explosion, and accordingly, analysts label the stock as a Buy with an average target price of $1.00. That represents a ...

Nov 30, 2023 · ATLANTA, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead, late-clinical stage product candidate and innovative therapeutic and diagnostic products, today announced the ...

ATLANTA, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead, late-clinical stage product candidate and innovative therapeutic and diagnostic products, today announced the ...

Femasys Inc ( FEMY) has fallen Tuesday morning, with the stock losing -1.54% in pre-market trading to 1.28. FEMY's short-term technical score of 47 indicates that the stock has traded less bullishly over the last month than 53% of stocks on the market. In the Medical Instruments & Supplies industry, which ranks 80 out of 146 industries, …Share this article. Femasys Inc. Announces the Appointment of James Liu, M.D., as Chief Medical Officer -- Thought leader from top-ranked academic gynecology …WebFEMY Stock 12 Months Forecast. Based on 4 Wall Street analysts offering 12 month price targets for Femasys in the last 3 months. The average price target is $10.67 with a high forecast of $13.00 and a low forecast of $7.00. The average price target represents a 620.95% change from the last price of $1.48.Nov 29, 2023 · 3 equities research analysts have issued twelve-month price targets for Femasys' shares. Their FEMY share price targets range from $7.00 to $10.00. On average, they expect the company's stock price to reach $9.00 in the next year. This suggests a possible upside of 884.9% from the stock's current price. View analysts price targets for FEMY or ... 12 Health Care Stocks Moving In Wednesday's After-Market Session. Gainers telesis bio (nasdaq:tbio) shares increased by 32.5% to $0.53 during wednesday's after-market session. Femasys shares rose 19.28% and axcella health shares rose 13.1%. Gyre therapeutics stock decreased by 8.67% and impel pharmaceuticals declined by 13.3%.Femasys Inc. is a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health.Femasys : FEMY got FDA ... This revolutionary clearance has primed ICU for an explosion, and accordingly, analysts label the stock as a Buy with an average target price of $1.00. That represents a ...

Find the latest Earnings Report Date for Femasys Inc. Common Stock (FEMY) at Nasdaq.com.Femasys, a medical device company, is set to launch its minimally invasive reproductive health products for women in 2024. ... Its stock ran from $0.33 to an …WebFinally, UBS Group AG grew its holdings in Femasys by 6,394.8% during the first quarter. UBS Group AG now owns 66,702 shares of the company’s stock valued at $151,000 after purchasing an additional 65,675 shares during the period. Institutional investors and hedge funds own 8.29% of the company’s stock. About Femasys (Get …Femasys Inc. analyst ratings, historical stock prices, earnings estimates & actuals. FEMY updated stock price target summary.Latest SEC filings for Femasys Inc. (FEMY). Entering text into the input field will update the search result belowThe Femasys Inc (NASDAQ: FEMY) stock price continued rallying higher on Monday following Friday’s 96% rally as investor sentiment towards the company remained decidedly bullish. The persistent demand for FEMY shares can be seen in its meticulous rally, with the stock now being up 578.51% over the past month.These promising developments of Femasys’s products further solidify the Buy rating. In another report released today, H.C. Wainwright also assigned a Buy rating to the stock with a $10.00 price ...

Jul 27, 2023 · InvestorPlace - Stock Market News, Stock Advice & Trading Tips. Shares of biomedical firm Femasys (NASDAQ:FEMY) more than doubled on Thursday.This followed an important intellectual property (IP ... Femasys’ FemBloc ® permanent birth control in late-stage clinical development is the first and only non-surgical, in-office, permanent birth control method intended to be a safer option for ...

Femasys Inc. (NASDAQ: FEMY) shares fell lower on Wednesday, a pullback from Tuesday's surge in price following the announcement that the company received FDA 510(k) clearance for FemaSeed, AIM ImmunoTech Inc. 0.47. -0.002. -0.4237%. Get Femasys Inc (FEMY:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Gainers Femasys Inc. (NASDAQ: FEMY) shares rose 201% to $1.00 in pre-market trading after the company received FDA 510(k) clearance for FemaSeed, an infertility treatment.At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life. Back. Femasys Inc. (FEMY) Add to watchlist. NasdaqCM - NasdaqCM Real Time Price. Currency in USD. 1.0300 +0.1162 (+12.72%) At close: …Gainers Femasys Inc. (NASDAQ: FEMY) shares rose 201% to $1.00 in pre-market trading after the company received FDA 510(k) clearance for FemaSeed, an infertility treatment.- The 510(k) Clearance from the United States Food and Drug Administration (FDA) allows for the U.S. commercialization of FemaSeed ®, an intratubal artificial insemination option designed to augment the natural fertilization process - - FemaSeed ® is an innovative infertility treatment designed to deliver sperm directly to where conception …Femasys (FEMY) Short Interest Ratio and Volume 2023. DOW 35,390.15. QQQ 389.51. Turned down for a loan, business owners look to family and even crowdsourcing to get money to grow. Important info on NVDA trade (Ad) 12 crew members are missing, 1 dead after a cargo ship sinks off a Greek island in stormy seas.Gainers Femasys Inc. (NASDAQ: FEMY) shares rose 201% to $1.00 in pre-market trading after the company received FDA 510(k) clearance for FemaSeed, an infertility treatment.Check Out Our Latest Research Report on Femasys. Femasys Stock Performance. NASDAQ:FEMY opened at $0.96 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.28 and a current ratio of 4.68. The firm’s 50-day moving average is $1.25 and its 200-day moving average is $0.81.Femasys Inc. FEMYNASDAQ FEMYNASDAQ 0.9138USD +0.0118 +1.31% At close at 16:59 UTC-8 See on Supercharts Overview News Ideas Financials Technicals Forecast …Web

Nov 28, 2023 · Femasys, a medical device company, is set to launch its minimally invasive reproductive health products for women in 2024. ... Its stock ran from $0.33 to an intraday high of $4.75 a few days ...

Apr 19, 2023 · ATLANTA, April 19, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women’s needs by developing a suite of products and product candidates that include ...

AIM ImmunoTech Inc. 0.47. -0.002. -0.4237%. Get Femasys Inc (FEMY:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Find the latest SEC Filings data for Femasys Inc. Common Stock (FEMY) at Nasdaq.com.Wall Street Stock Market & Finance report, prediction for the future: You'll find the Femasys share forecasts, stock quote and buy / sell signals below. According to present data Femasys's FEMY shares and potentially its market environment have been in bearish cycle last 12 months (if exists).Overview. Femasys Inc. is a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health.Institutional Ownership and Shareholders. Femasys Inc (US:FEMY) has 32 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 1,650,299 shares. Largest shareholders include Clear Street Llc, Clear Creek Financial Management, LLC, Bank Of America ...With stocks at historic highs, many individuals are wondering if the time is right to make their first foray in the stock market. The truth is, there is a high number of great stocks to buy today. However, you might be unsure how to begin.The Femasys Inc. stock price fell by -3.27% on the last day (Wednesday, 29th Nov 2023) from $1.01 to $0.98. During the last trading day the stock fluctuated 6.91% from a day low at $0.96 to a day high of $1.03. The price has fallen in 5 of the last 10 days but is still up by 5.05% over the past 2 weeks.-- Thought leader from top-ranked academic gynecology program to lead clinical and medical affairs at Femasys --ATLANTA, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible …Oct 26, 2023 · Oct. 26, 2023, 08:30 AM. – Completion of the European Union Medical Device Regulation (MDR) final audit is the last step in obtaining an MDR certificate and CE marking, confirming Femasys ...

These promising developments of Femasys’s products further solidify the Buy rating. In another report released today, H.C. Wainwright also assigned a Buy rating to the stock with a $10.00 price ...At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life. Back. Femasys Inc. (FEMY) Add to watchlist. NasdaqCM - NasdaqCM Real Time Price. Currency in USD. 1.0300 +0.1162 (+12.72%) At close: …Femasys is a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead revolutionary late ...Instagram:https://instagram. bah booztop broker forexcyxthow to day trade for beginners ATLANTA, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office ...ATLANTA, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead, late-clinical stage product candidate and innovative therapeutic and diagnostic products, today announced the ... best treasury etfspsww stock SEC Filings. Select Year: Filter filing type: Date Filing Type Filing Description Download / View. 11/30/2023. S-3. Securities Registration Statement (simplified form) 11/29/2023. 8-K. Current report filing.LAS VEGAS, November 15, 2023--PharmaCyte Biotech, Inc. (Nasdaq: PMCB) ("PharmaCyte" or the "Company") announces it has made a $5 million investment in Femasys, Inc. (Nasdaq:FEMY) ("Femasys"), a biomedical company focused on meeting significant unmet needs for women worldwide. Femasys offers a broad portfolio of in … what is the future of silver FEMY Earnings Date and Information. Femasys has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, April 4th, 2024 based off prior year's report dates. Read More.Femasys Inc. (NASDAQ: FEMY) shares are trading higher Friday after HC Wainwright maintained a Buy rating on the stock and raised its price target from $5 to $13.Femasys has received 510 (k) Clearance from the FDA for FemaSeed®, an innovative infertility treatment. The clearance allows for the U.S. commercialization of FemaSeed®, which delivers sperm directly to the fallopian tube. FemaSeed® is expected to reduce procedural complications compared to other treatments.